The relationship between respiratory syncytial virus (RSV) strain and disease severity was assessed in 265 hospitalized infants over a 3-year period (1988)(1989)(1990)(1991). A severity index of clinical and physiologic parameters was used to grade illness severity. Multivariate analysis of 134 infants infected with group A RSV strains and 131 infants infected with group B strains indicated that prematurity, underlying medical conditions, group A RSV infection, and age £ 3 months were independently associated with severe disease. Odds ratios for severe disease for these risk factors were 1.83, 2.84, 3.26, and 4.39, respectively. Among infants without underlying medical conditions, group B RSV infection rarely required ventilatory support, in contrast to group A infections (1/90 vs. 13/107; P < .006), and had significantly lower severity indices (mean ± SD, 0.6 ± 9 vs. 1.3 ± 1.9; P = .05). Results confirm earlier findings that group A RSV infection results in greater disease severity than group B infection among hospitalized infants. Certain host factors have been associated with severe disease during primary R S V infection. Foremost among these are young age ( < 3 months), prematurity, and the presence o f un derlying cardiopulmonary or immunosuppressive conditions [7, 8] . In addition, lower socioeconom ic status, exposure to ciga rette smoke, household crowding, lack o f breast-feeding, and low levels o f passively acquired maternal antibody have also been associated with greater disease burden in some reports In an attempt to either validate or refute our original findings, w e report the results o f a 3-year prospective replication study in 324 additional hospitalized infants; the study used identical methods o f enrollment, data collection, and severity scoring.
virus type 1, clinical disease presentation and severity often vary with the infecting strain [12, 13] . R S V isolates can be [20] . Initial descriptions o f the epidem iology o f R S V strains did not suggest clinical differences [18] . H ow ever, in a 2-year prospective analysis o f 157 hospitalized in fants, w e found that group A R S V infections were associated with greater illness severity than group B infections [21] . In the analysis o f these infants, w e used objective clinical findings and laboratory measurements to derive and validate a severity index to quantitate illness severity. Multivariate analysis indi cated that infection with a group A R S V strain was o f the same importance as premature birth or underlying conditions in predicting a high severity index. Nevertheless, other published reports provide conflicting results concerning the importance o f strain variation on illness severity [2 2 -3 2 ].
In an attempt to either validate or refute our original findings, w e report the results o f a 3-year prospective replication study in 324 additional hospitalized infants; the study used identical methods o f enrollment, data collection, and severity scoring.
Methods
Subjects. All infants admitted to the University o f Rochester' s Strong Memorial Hospital with respiratory tract infection during the winters o f [1988] [1989] [1989] [1990] , and 1990-1991 were pro spectively evaluated for RSV infection. During the 3-year period, infection was confirmed in 324 children, o f whom 24 were ex cluded because they were > 2 4 months o f age. O f the remaining 300 subjects, the virus isolate could not be typed for 35 , thus leaving 265 subjects identified as having group A or B infection who were used in the analysis.
D em ographic and clinical data. Information on demographic and potentially confounding variables collected for all infants in cluded sex, race, gestational age, family size, age at admission, family history o f atopy, prior wheezing history, breast-feeding history, socioeconomic status, smoking by the mother or others in the household, and the presence and severity o f specific underlying medical conditions. Underlying conditions included bronchopul monary dysplasia, cystic fibrosis, a prior diagnosis o f asthma, con genital heart disease, immunodeficiency states (human immunode ficiency virus infection, leukemia, chemotherapy for malignancy, and Down's syndrome), and neuromuscular or swallowing disor ders that compromise pulmonary function. Clinical and laboratory data were collected daily until discharge and recorded on a stan dardized form. This included vital signs, presence o f rales, wheezes, stridor, retractions, or cyanosis, and the occurrence o f apnea. Supplemental oxygen use and arterial blood gas values or oximetry were recorded when available. As in the prior study, for the 13 subjects (4% ) in whom blood gas measurements or oximetry were not performed, results were assumed to not reach the cutoff threshold for the severity score. Requirements for mechanical ven tilation and length o f stay (LOS) were recorded. For nosocomial infections, LOS was assigned a value equal to the median for all other subjects, which was 5 days.
Severity index. The index used to measure severity o f illness was identical to that used in our prior study, and its development has been described in detail [21] . Selection o f items for inclusion in the index was based on ability to distinguish patients known to be at high versus low risk for severe disease. A single point each was assigned for apnea in the hospital, pH <7.35, P c o 2 > 45, arterial S o2 < 87 % , and LOS > 5 days, and 2 points were assigned if mechanical ventilation was required. Scores on the severity index ranged from a minimum o f 0 to a maximum o f 7.
Laboratory methods. A diagnosis o f RSV infection was made by virus isolation or by antigen detection using a commercial direct immunofluorescent monoclonal antibody test (Genetic Systems, Seattle). Nasal wash specimens were collected for viral culture on HEp-2 cells, and respiratory epithelial cells were recovered from nasal swabs for RSV antigen detection by immunofluorescence according to published methods [21] . RSV isolates were identified by typical syncytial cytopathic effect and confirmed by direct im munofluorescence. Isolates were passaged and strain typed into group A or B RSV by reactivity with monoclonal antibodies to the RSV fusion (F) and attachment (G) proteins as previously described [21] .
Statistical analysis. Tabular analysis was performed with the X 2 statistic for significance testing. Comparisons between mean values were assessed with Student's t test whenever assumptions were met. The Mann-Whitney (W ilcoxon rank sum) test was used to compare values for nonnormally distributed interval and ordinal variables. Log-linear (logit) analysis o f multidimensional tables was performed with the Newton-Raphson estimation procedure [33] . The resulting L estimates are maximum likelihood estimates. though it did not reach statistical significance (11.9% vs. 5.3% ; P = .062).
In our previous study, the severity index was found to be significantly greater in infants with underlying medical condi tions, premature birth, age £ 3 months, and ribavirin treatment, thus lending support to its validity as a measure o f severity.
A s in our prior study, a severity index § 3 was defined as severe disease. In the current analysis, the distribution o f sever ity indices ranged from 0 to 7 for group A infections and from 0 to 6 for group B infections. For both groups, the severity indices were not normally distributed but skewed towards low scores, w hich is the expected pattern for a severity scoring system. For group A , the median, mean, and SD were 1, 1.34, and 1.83, respectively, while for group B infants they were 1, 0.89, and 1.21. Although this difference in distribution for the entire group was not statistically significant when analyzed by the Mann-W hitney rank order test, group A -in fe c te d infants were three times m ore likely to have a severity index § 3 than were group B -in fe c te d infants (20.7% vs. 7.6% ; P = .006). 
Discussion
Until the availability o f monoclonal antibodies, R S V was thought to be a single homotypic virus that caused a spectrum o f illness from the com m on cold to bronchiolitis and pneumonia.
Variation in illness severity was generally attributed to various This is in contrast to our previous study, in w hich prematurity was independently linked to severe disease. Groothius et al. [34] noted that prematurity itself may only be a risk factor for Finally, a prospective serologic survey o f ~8 0 newborn infants per winter found that the RSV-specific attack rate during the com bined group B -dom inant years was only slightly less than the attack rate in the group A -d om in a n t year (67% vs. 77% ).
Taken together, these analyses indicate that it is unlikely that the difference in severity seen among the hospitalized infants with group A virus was related to a higher attack rate for group [25] did not find a relationship between R S V strain and severity in a study encompassing a spectrum o f Canadian hospitals.
H owever, they were able to identify the R S V group in only half o f the study population, and there was m ethodologic variability among the cooperating centers. In contrast, Taylor et al. [27] reported significantly greater requirements for ventilation, sup plemental oxygen, and tube feeding during retrospective analy sis o f nearly 300 group A -in fe c te d infants during 19 7 4 -1 9 8 8 .
Similarly, Heikkinen et al. [22] found that oxygen therapy was Hendry et al. [18] 1981-1982 USA 51A/34B R/ND = Mufson et al. [19] 1981-1986 USA 155A/51B R/D A Hendry et al. [26] 1983-1985 USA 125A/92B R/ND = Taylor et al. [27] 1974 [23] 1989-1991 Australia 337A/107B P/D = Mufson et al. [29] 1978 -1988 USA 319A/86B R/D X Hall et al. [20] 1975 -1990 USA 858A/351B R/D A Wilson et al. [30] 1987-1988 Canada 45A/24B R/D = Wang et al. [25] 1993 Canada 102A/250B P/D/MV = Salomon et al. [31] 1987-1988 Argentina 23A/93B R/ND A Tsutsumi et al. [24] 1980-1989 Japan 77A/52B R/ND = Heikkinen et al. [22] 1987-1992 Finland 192A/134B P/D A Russi et al. [32] 1985-1987 Uruguay 19A/22B P/D = Current report 1988-1991 USA 134A/131B P/D/SI/MV A * R = retrospective study; P = prospective study; ND = severity scoring and/or clinical measures of illness not described; D = clinical description of illness used as severity indicator; SI = use of composite severity index; MV = multivariate analysis applied to data.
1 Clinical disease and severity of group A and group B RSV similar (=); severity not described, but differences in clinical illness noted (X); group A virus more severe (A).
T he significance o f these findings is speculative. C linical m anagem ent generally can n o t aw ait determ ination o f the in fecting strain, although recent advances in diagnostic tests u s ing polym erase chain reactio n can discrim inate R SV groups and m ay allow rap id determ ination o f R SV group in the future [36] . These findings m ay suggest th at vaccine developm ent should be directed at group A viruses, although group B R SV epidem ics are also responsible for a large n u m b er o f h o sp ital izations each year. M ore relevant, how ever, m ay be th at devel opm ent o f a live attenuated R S V vaccine m ay optim ally be derived from a group B virus, rath er th an a group A virus, since excessive virulence has b een an im portant reaso n for failure o f live attenuated vaccines in the past [37] . R ecently, C row e et al. [38] pro d u ced several live attenuated group B vaccine candidates. It w ill be o f interest to com pare th eir v iru lence w ith sim ilarly prepared attenuated group A vaccines, especially in the youngest infants w ho are at g reatest risk for adverse events.
In conclusion, these results confirm our earlier finding that group A R SV infections resu lt in m ore severe clinical disease th an group B R SV infections am ong h ospitalized infants. R e f e r e n c e s
